数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Ira E. Ritter Director 74 9.55万美元 未持股 2023-06-02
Matthew Korenberg Director 48 7.24万美元 未持股 2023-06-02
Michael Poirier Chairman and Chief Executive Officer 67 72.85万美元 未持股 2023-06-02
Richard David Director 63 6.97万美元 未持股 2023-06-02
Sidney Emery, Jr. Director 77 7.78万美元 未持股 2023-06-02
Matthew Korenberg Director 48 未披露 未持股 2023-06-02
Kurt Kruger Director 67 6.97万美元 未持股 2023-06-02

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Michael Poirier Chairman and Chief Executive Officer 67 72.85万美元 未持股 2023-06-02
Amy Broidrick -- President, Chief Strategy and Operating Officer 65 50.80万美元 未持股 2023-06-02
Christopher Lotz Chief Financial Officer, Vice President of Finance 58 未披露 未持股 2023-06-02
Tariq Arshad Chief Medical Officer and Senior Vice President 53 43.97万美元 未持股 2023-06-02

董事简历

中英对照 |  中文 |  英文
Ira E. Ritter

Ira E. Ritter,曾担任Qualigen Therapeutics, Inc.的前身Ritter Pharmaceuticals, Inc.的联合创始人、首席战略官和执行主席(从2004年成立到2008年Ritter Pharmaceuticals, Inc.成立),并从2008年到2020年5月22日在Ritter Pharmaceuticals, Inc.担任这些职位,反向资本重组交易(“反向资本重组交易”)。公司更名为Qualigen Therapeutics, Inc.Ritter先生拥有创建和建立多元化商业企业的丰富经验,自1987年以来,他通过Andela Corporation(他担任首席执行官)为广泛的细分市场提供企业管理、战略规划和财务咨询,包括;健康产品相关全国分销及自有品牌制作、电视及出版。他协助Ritter Pharmaceuticals, Inc.在纳斯达克上市,Martin Lawrence Art Galleries在纽约证券交易所上市。自2010年以来,Ritter先生还担任Stonehenge Partners, LLC的管理合伙人。Ritter先生拥有长期的公共服务历史,包括被三位州长任命为几个加州委员会的成员,其中包括担任加州监狱行业管理局(California Prison Industry Authority)专员八年。


Ira E. Ritter,served as Co-Founder, Chief Strategic Officer and Executive Chairman of Qualigen Therapeutics, Inc. predecessor, Ritter Pharmaceuticals, Inc., from its inception in 2004 through the formation of Ritter Pharmaceuticals, Inc. in 2008 and served in those positions with Ritter Pharmaceuticals, Inc. from 2008 until the May 22, 2020 reverse recapitalization transaction (the "Reverse Recapitalization Transaction") in which Ritter Pharmaceuticals, Inc. changed its name to Qualigen Therapeutics, Inc. Mr. Ritter has extensive experience creating and building diverse business enterprises and since 1987 through Andela Corporation, of which he is the CEO, has provided corporate management, strategic planning and financial consulting for a wide range of market segments including; health product related national distribution and private label production, television and publishing. He assisted taking Ritter Pharmaceuticals, Inc. public on Nasdaq and Martin Lawrence Art Galleries public on the New York Stock Exchange. Since 2010, Mr. Ritter has also acted as a managing partner of Stonehenge Partners, LLC. Mr. Ritter has a long history of public service that includes appointments by three Governors to several State of California Commissions including eight years as Commissioner on the California Prison Industry Authority.
Ira E. Ritter,曾担任Qualigen Therapeutics, Inc.的前身Ritter Pharmaceuticals, Inc.的联合创始人、首席战略官和执行主席(从2004年成立到2008年Ritter Pharmaceuticals, Inc.成立),并从2008年到2020年5月22日在Ritter Pharmaceuticals, Inc.担任这些职位,反向资本重组交易(“反向资本重组交易”)。公司更名为Qualigen Therapeutics, Inc.Ritter先生拥有创建和建立多元化商业企业的丰富经验,自1987年以来,他通过Andela Corporation(他担任首席执行官)为广泛的细分市场提供企业管理、战略规划和财务咨询,包括;健康产品相关全国分销及自有品牌制作、电视及出版。他协助Ritter Pharmaceuticals, Inc.在纳斯达克上市,Martin Lawrence Art Galleries在纽约证券交易所上市。自2010年以来,Ritter先生还担任Stonehenge Partners, LLC的管理合伙人。Ritter先生拥有长期的公共服务历史,包括被三位州长任命为几个加州委员会的成员,其中包括担任加州监狱行业管理局(California Prison Industry Authority)专员八年。
Ira E. Ritter,served as Co-Founder, Chief Strategic Officer and Executive Chairman of Qualigen Therapeutics, Inc. predecessor, Ritter Pharmaceuticals, Inc., from its inception in 2004 through the formation of Ritter Pharmaceuticals, Inc. in 2008 and served in those positions with Ritter Pharmaceuticals, Inc. from 2008 until the May 22, 2020 reverse recapitalization transaction (the "Reverse Recapitalization Transaction") in which Ritter Pharmaceuticals, Inc. changed its name to Qualigen Therapeutics, Inc. Mr. Ritter has extensive experience creating and building diverse business enterprises and since 1987 through Andela Corporation, of which he is the CEO, has provided corporate management, strategic planning and financial consulting for a wide range of market segments including; health product related national distribution and private label production, television and publishing. He assisted taking Ritter Pharmaceuticals, Inc. public on Nasdaq and Martin Lawrence Art Galleries public on the New York Stock Exchange. Since 2010, Mr. Ritter has also acted as a managing partner of Stonehenge Partners, LLC. Mr. Ritter has a long history of public service that includes appointments by three Governors to several State of California Commissions including eight years as Commissioner on the California Prison Industry Authority.
Matthew Korenberg

Matthew Korenberg自2015年8月以来一直担任我们的Vice President,财务和首席财务官。在加入Ligand之前,从2013年9月开始,Korenberg先生是NeuroCircuit Therapeutics的创始人,首席执行官和董事,该公司专注于开发药物来治疗大脑的遗传疾病,最初专注于唐氏综合征。在创立NeuroCircuit Therapeutics之前,1999年7月至2013年8月,科伦伯格先生是高盛(Goldman Sachs)的董事总经理兼梦百合投资银行团队成员。在高盛(Goldman Sachs)的14年任期内,Korenberg先生专注于为生物技术和制药部门的公司提供建议和融资,总部位于纽约、伦敦和旧金山。在高盛(Goldman Sachs)之前,科伦伯格是Dillon,Read&Co.梦百合投资银行家。在那里,他花了两年时间在生物技术和制药部门以及工业公司的梦百合公司工作。Korenberg先生拥有密歇根大学(University of Michigan)的财务与会计学士学位。


Matthew Korenberg has served as LIGAND PHARMACEUTICALS INC Vice President, Finance and Chief Financial Officer since August 2015. Prior to joining Ligand, commencing in September 2013 Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Prior to founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Prior to Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.
Matthew Korenberg自2015年8月以来一直担任我们的Vice President,财务和首席财务官。在加入Ligand之前,从2013年9月开始,Korenberg先生是NeuroCircuit Therapeutics的创始人,首席执行官和董事,该公司专注于开发药物来治疗大脑的遗传疾病,最初专注于唐氏综合征。在创立NeuroCircuit Therapeutics之前,1999年7月至2013年8月,科伦伯格先生是高盛(Goldman Sachs)的董事总经理兼梦百合投资银行团队成员。在高盛(Goldman Sachs)的14年任期内,Korenberg先生专注于为生物技术和制药部门的公司提供建议和融资,总部位于纽约、伦敦和旧金山。在高盛(Goldman Sachs)之前,科伦伯格是Dillon,Read&Co.梦百合投资银行家。在那里,他花了两年时间在生物技术和制药部门以及工业公司的梦百合公司工作。Korenberg先生拥有密歇根大学(University of Michigan)的财务与会计学士学位。
Matthew Korenberg has served as LIGAND PHARMACEUTICALS INC Vice President, Finance and Chief Financial Officer since August 2015. Prior to joining Ligand, commencing in September 2013 Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Prior to founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Prior to Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.
Michael Poirier

Michael Poirier,1996年创立Qualigen公司,现任董事长兼首席执行官。在创立Qualigen之前,Poirier先生曾在Ashirus Technologies,Inc.,EnSys,Inc.,赛诺菲巴斯德和雅培公司担任相关的运营、营销和销售职位。在雅培工作之前,Poirier先生曾在美国海军担任军官,被分配到美国大西洋舰队。Poirier先生拥有普罗维登斯学院的学士学位,并曾就读于瑞士苏黎世大学法学院。


Michael Poirier,founded the Qualigen business in 1996 and is its Chairman and Chief Executive Officer. Before founding Qualigen, Mr. Poirier had relevant operating, marketing and sales positions with Ashirus Technologies, Inc., EnSys, Inc., Sanofi Pasteur and Abbott Laboratories, Inc. Before working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Zurich, Switzerland, School of Law.
Michael Poirier,1996年创立Qualigen公司,现任董事长兼首席执行官。在创立Qualigen之前,Poirier先生曾在Ashirus Technologies,Inc.,EnSys,Inc.,赛诺菲巴斯德和雅培公司担任相关的运营、营销和销售职位。在雅培工作之前,Poirier先生曾在美国海军担任军官,被分配到美国大西洋舰队。Poirier先生拥有普罗维登斯学院的学士学位,并曾就读于瑞士苏黎世大学法学院。
Michael Poirier,founded the Qualigen business in 1996 and is its Chairman and Chief Executive Officer. Before founding Qualigen, Mr. Poirier had relevant operating, marketing and sales positions with Ashirus Technologies, Inc., EnSys, Inc., Sanofi Pasteur and Abbott Laboratories, Inc. Before working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Zurich, Switzerland, School of Law.
Richard David

本文作者是美国南加州最大的泌尿科集团创世纪医疗合作伙伴洛杉矶分部的首席医疗官。他还担任Genesis的晚期前列腺癌卓越中心的医学主任。此外,David博士还担任加州大学洛杉矶分校David Geffen医学院泌尿外科临床教授。戴维博士在斯坦福大学获得本科教育,在费城的托马斯·杰斐逊大学获得医学学位。他还拥有南加州大学马歇尔商学院的医学管理硕士学位(MMM)。他接受了普通外科的培训,并在洛杉矶的加州大学洛杉矶分校医学中心完成了泌尿科住院医师的工作。戴维博士是美国外科医生学会的研究员。


Richard David,serves as Chief Medical Officer for the Los Angeles Division of Genesis Healthcare Partners, the largest urology group in Southern California. He also serves as medical director for Genesis' Advanced Prostate Cancer Center of Excellence. In addition, Dr. David serves as Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. Dr. David obtained his undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He also holds a Master's degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California. He trained in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the American College of Surgeons.
本文作者是美国南加州最大的泌尿科集团创世纪医疗合作伙伴洛杉矶分部的首席医疗官。他还担任Genesis的晚期前列腺癌卓越中心的医学主任。此外,David博士还担任加州大学洛杉矶分校David Geffen医学院泌尿外科临床教授。戴维博士在斯坦福大学获得本科教育,在费城的托马斯·杰斐逊大学获得医学学位。他还拥有南加州大学马歇尔商学院的医学管理硕士学位(MMM)。他接受了普通外科的培训,并在洛杉矶的加州大学洛杉矶分校医学中心完成了泌尿科住院医师的工作。戴维博士是美国外科医生学会的研究员。
Richard David,serves as Chief Medical Officer for the Los Angeles Division of Genesis Healthcare Partners, the largest urology group in Southern California. He also serves as medical director for Genesis' Advanced Prostate Cancer Center of Excellence. In addition, Dr. David serves as Clinical Professor of Urology for the David Geffen School of Medicine at UCLA. Dr. David obtained his undergraduate education at Stanford University and his medical degree at Thomas Jefferson University in Philadelphia. He also holds a Master's degree in Medical Management (MMM) from the Marshall School of Business at the University of Southern California. He trained in general surgery and completed his urology residency at UCLA Medical Center in Los Angeles. Dr. David is a fellow of the American College of Surgeons.
Sidney Emery, Jr.

Sidney Emery,Jr.于2010年收购了Supply Chain Services,并作为其首席执行官将其发展成为自动识别和数据捕获以及工厂自动化解决方案的主要供应商,然后于2020年5月将该业务出售给Sole Source Capital有限责任公司。在加入供应链服务之前,他曾担任MTS系统科技公司(Nasdaq-GS:MTSC)的董事长兼首席执行官,该公司是机械测试系统和高性能工业位置传感器的全球领先供应商。2006年至2018年,埃默里先生在明尼苏达州公用事业和能源公司Allete, Inc.(纽约证券交易所代码:ALE)担任董事会成员。埃默里先生担任圣托马斯大学工程学院理事会主席。埃默里拥有斯坦福大学工业工程博士学位和美国海军学院工程学学士学位。他曾在美国海军服役10年(包括在越南的炮舰上服役)


Sidney Emery, Jr.,acquired Supply Chain Services in 2010 and, as its Chief Executive Officer, grew it into a premier provider of automatic identification and data capture and factory automation solutions before selling the business to Sole Source Capital LLC in May 2020. Before Supply Chain Services, he served as Chairman and Chief Executive Officer of MTS Systems Corporation (Nasdaq-GS: MTSC), a leading global supplier of mechanical testing systems and high-performance industrial position sensors. Mr. Emery served on the Board of Directors of Allete, Inc. (NYSE: ALE), a Minnesota-based utilities and energy company, from 2006 to 2018. Mr. Emery chairs the University of St. Thomas School of Engineering Board of Governors. Mr. Emery holds a PhD in Industrial Engineering from Stanford University and a B.S. in Engineering from the US Naval Academy. He served for 10 years in the US Navy (including on gunboats in Vietnam
Sidney Emery,Jr.于2010年收购了Supply Chain Services,并作为其首席执行官将其发展成为自动识别和数据捕获以及工厂自动化解决方案的主要供应商,然后于2020年5月将该业务出售给Sole Source Capital有限责任公司。在加入供应链服务之前,他曾担任MTS系统科技公司(Nasdaq-GS:MTSC)的董事长兼首席执行官,该公司是机械测试系统和高性能工业位置传感器的全球领先供应商。2006年至2018年,埃默里先生在明尼苏达州公用事业和能源公司Allete, Inc.(纽约证券交易所代码:ALE)担任董事会成员。埃默里先生担任圣托马斯大学工程学院理事会主席。埃默里拥有斯坦福大学工业工程博士学位和美国海军学院工程学学士学位。他曾在美国海军服役10年(包括在越南的炮舰上服役)
Sidney Emery, Jr.,acquired Supply Chain Services in 2010 and, as its Chief Executive Officer, grew it into a premier provider of automatic identification and data capture and factory automation solutions before selling the business to Sole Source Capital LLC in May 2020. Before Supply Chain Services, he served as Chairman and Chief Executive Officer of MTS Systems Corporation (Nasdaq-GS: MTSC), a leading global supplier of mechanical testing systems and high-performance industrial position sensors. Mr. Emery served on the Board of Directors of Allete, Inc. (NYSE: ALE), a Minnesota-based utilities and energy company, from 2006 to 2018. Mr. Emery chairs the University of St. Thomas School of Engineering Board of Governors. Mr. Emery holds a PhD in Industrial Engineering from Stanford University and a B.S. in Engineering from the US Naval Academy. He served for 10 years in the US Navy (including on gunboats in Vietnam
Matthew Korenberg

Matthew Korenberg,自2022年11月起担任Ligand Pharmaceuticals Incorporated(纳斯达克:LGND)总裁兼首席运营官,该公司是一家生物制药公司,专注于开发或获取帮助制药公司发现和开发药物的技术,在此之前自2015年8月起担任Ligand Pharmaceuticals Incorporated执行副总裁、财务和首席财务官。在2013年9月加入Ligand之前,Korenberg先生是NeuroCircuit Therapeutics公司的创始人、首席执行官和董事。NeuroCircuit Therapeutics公司专注于开发治疗大脑遗传疾病的药物,最初专注于唐氏综合症。在创立NeuroCircuit Therapeutics之前,Korenberg先生于1999年7月至2013年8月担任高盛高盛董事总经理和医疗保健投资银行团队成员。在高盛高盛任职的14年期间,科伦伯格先生主要为生物技术和制药行业的公司提供咨询和融资,并在纽约、伦敦和旧金山工作。在加入高盛之前,科伦伯格是Dillon,Read & Co. Inc.的一名医疗保健投资银行家,在那里,他在生物技术和制药行业的医疗保健公司以及工业公司工作了两年。Korenberg先生拥有密歇根大学金融和会计学学士学位。


Matthew Korenberg,has served as President and Chief Operating Officer of Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, since November 2022, and before that as Executive Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated since August 2015. Before joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Before founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Before Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from the University of Michigan.
Matthew Korenberg,自2022年11月起担任Ligand Pharmaceuticals Incorporated(纳斯达克:LGND)总裁兼首席运营官,该公司是一家生物制药公司,专注于开发或获取帮助制药公司发现和开发药物的技术,在此之前自2015年8月起担任Ligand Pharmaceuticals Incorporated执行副总裁、财务和首席财务官。在2013年9月加入Ligand之前,Korenberg先生是NeuroCircuit Therapeutics公司的创始人、首席执行官和董事。NeuroCircuit Therapeutics公司专注于开发治疗大脑遗传疾病的药物,最初专注于唐氏综合症。在创立NeuroCircuit Therapeutics之前,Korenberg先生于1999年7月至2013年8月担任高盛高盛董事总经理和医疗保健投资银行团队成员。在高盛高盛任职的14年期间,科伦伯格先生主要为生物技术和制药行业的公司提供咨询和融资,并在纽约、伦敦和旧金山工作。在加入高盛之前,科伦伯格是Dillon,Read & Co. Inc.的一名医疗保健投资银行家,在那里,他在生物技术和制药行业的医疗保健公司以及工业公司工作了两年。Korenberg先生拥有密歇根大学金融和会计学学士学位。
Matthew Korenberg,has served as President and Chief Operating Officer of Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines, since November 2022, and before that as Executive Vice President, Finance and Chief Financial Officer of Ligand Pharmaceuticals Incorporated since August 2015. Before joining Ligand, commencing in September 2013, Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Before founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July 1999 through August 2013. During his 14 year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Before Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read & Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from the University of Michigan.
Kurt Kruger

Kurt Kruger在医疗技术领域拥有30年的职业生涯。他在该领域的深度参与,从生物医学工程师的产品设计和开发,到为上市医疗产品公司筹集资金,并以股票研究分析师的身份关注上市医疗产品公司。作为Guidant的营销经理,他制定了首个植入式除颤器的发布计划,Guidant现在是波士顿科学的一部分。作为一名证券分析师,他表现出了敏锐的洞察力,带领Hambrecht & Quist为Ventritex提供风险资金,然后上市,该公司后来被圣犹达医疗收购。在Hambrecht & Quist之后,克鲁格曾在蒙哥马利证券公司和美国银行担任分析师。在20年的研究工作中,克鲁格监督了30多家医疗产品公司的IPO,包括领导WR Hambrecht & Co的生命科学银行业务。克鲁格获得了布朗大学生物医学工程学副学士学位、密歇根大学生物工程硕士学位和麻省理工学院斯隆商学院商学学位。他还在哥伦比亚大学完成了医学预科后学士学位课程。


Kurt Kruger,has enjoyed a 30-year career in medical technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Mr. Kruger worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Mr. Kruger has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master's degree in Bioengineering from the University of Michigan; and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.
Kurt Kruger在医疗技术领域拥有30年的职业生涯。他在该领域的深度参与,从生物医学工程师的产品设计和开发,到为上市医疗产品公司筹集资金,并以股票研究分析师的身份关注上市医疗产品公司。作为Guidant的营销经理,他制定了首个植入式除颤器的发布计划,Guidant现在是波士顿科学的一部分。作为一名证券分析师,他表现出了敏锐的洞察力,带领Hambrecht & Quist为Ventritex提供风险资金,然后上市,该公司后来被圣犹达医疗收购。在Hambrecht & Quist之后,克鲁格曾在蒙哥马利证券公司和美国银行担任分析师。在20年的研究工作中,克鲁格监督了30多家医疗产品公司的IPO,包括领导WR Hambrecht & Co的生命科学银行业务。克鲁格获得了布朗大学生物医学工程学副学士学位、密歇根大学生物工程硕士学位和麻省理工学院斯隆商学院商学学位。他还在哥伦比亚大学完成了医学预科后学士学位课程。
Kurt Kruger,has enjoyed a 30-year career in medical technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Mr. Kruger worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Mr. Kruger has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master's degree in Bioengineering from the University of Michigan; and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.

高管简历

中英对照 |  中文 |  英文
Michael Poirier

Michael Poirier,1996年创立Qualigen公司,现任董事长兼首席执行官。在创立Qualigen之前,Poirier先生曾在Ashirus Technologies,Inc.,EnSys,Inc.,赛诺菲巴斯德和雅培公司担任相关的运营、营销和销售职位。在雅培工作之前,Poirier先生曾在美国海军担任军官,被分配到美国大西洋舰队。Poirier先生拥有普罗维登斯学院的学士学位,并曾就读于瑞士苏黎世大学法学院。


Michael Poirier,founded the Qualigen business in 1996 and is its Chairman and Chief Executive Officer. Before founding Qualigen, Mr. Poirier had relevant operating, marketing and sales positions with Ashirus Technologies, Inc., EnSys, Inc., Sanofi Pasteur and Abbott Laboratories, Inc. Before working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Zurich, Switzerland, School of Law.
Michael Poirier,1996年创立Qualigen公司,现任董事长兼首席执行官。在创立Qualigen之前,Poirier先生曾在Ashirus Technologies,Inc.,EnSys,Inc.,赛诺菲巴斯德和雅培公司担任相关的运营、营销和销售职位。在雅培工作之前,Poirier先生曾在美国海军担任军官,被分配到美国大西洋舰队。Poirier先生拥有普罗维登斯学院的学士学位,并曾就读于瑞士苏黎世大学法学院。
Michael Poirier,founded the Qualigen business in 1996 and is its Chairman and Chief Executive Officer. Before founding Qualigen, Mr. Poirier had relevant operating, marketing and sales positions with Ashirus Technologies, Inc., EnSys, Inc., Sanofi Pasteur and Abbott Laboratories, Inc. Before working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Zurich, Switzerland, School of Law.
Amy Broidrick
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Christopher Lotz

Christopher Lotz于2002年加入Qualigen,担任财务总监,2003年晋升为现任首席财务官和财务副总裁。在加入Qualigen之前的15年里,洛茨先后在亚洲软件开发商Bexcom、定制家具制造商California Furniture Collections,Inc.和教育媒体出版商Group Publishing,Inc.担任财务领导职务。洛茨先生拥有科罗拉多州立大学工商管理学士学位。


Christopher Lotz,joined Qualigen as Director of Finance in 2002 and was promoted to his current role of Chief Financial Officer, Vice President of Finance in 2003. Before joining Qualigen, Mr. Lotz spent the previous 15 years serving in financial leadership positions with Bexcom, an Asian-based software developer, California Furniture Collections, Inc., a custom furniture manufacturer, and Group Publishing, Inc., an educational media publisher. Mr. Lotz holds a B.S. in Business Administration from Colorado State University.
Christopher Lotz于2002年加入Qualigen,担任财务总监,2003年晋升为现任首席财务官和财务副总裁。在加入Qualigen之前的15年里,洛茨先后在亚洲软件开发商Bexcom、定制家具制造商California Furniture Collections,Inc.和教育媒体出版商Group Publishing,Inc.担任财务领导职务。洛茨先生拥有科罗拉多州立大学工商管理学士学位。
Christopher Lotz,joined Qualigen as Director of Finance in 2002 and was promoted to his current role of Chief Financial Officer, Vice President of Finance in 2003. Before joining Qualigen, Mr. Lotz spent the previous 15 years serving in financial leadership positions with Bexcom, an Asian-based software developer, California Furniture Collections, Inc., a custom furniture manufacturer, and Group Publishing, Inc., an educational media publisher. Mr. Lotz holds a B.S. in Business Administration from Colorado State University.
Tariq Arshad

塔里克·阿尔沙德,在2021年5月加入Qualigen之前,阿尔沙德博士曾于2019年至2021年在加利福尼亚州圣何塞的Becton Dickinson Biosciences担任全球医疗事务和临床研究主管,在那里,他领导了一个由医学博士和博士组成的团队,推动以免疫肿瘤学为重点的前沿产品组合的科学战略。从2018年至2019年,Arshad博士担任赛诺菲 Genyzyme全球市场医疗事务、免疫学主管,从2016年至2018年担任Humanigen公司首席医疗官、临床研究和医疗事务主管。在此之前,他曾在XOMA公司、基因泰克、默克制药公司和辉瑞公司担任领导职务。阿尔沙德博士拥有旁遮普大学的医学学士学位、外国医学毕业生教育委员会(ECFMG)的医学学士学位和乔治华盛顿大学的工商管理硕士学位。


Tariq Arshad,Prior to joining Qualigen in May 2021, Dr. Arshad was Global Head of Medical Affairs and Clinical Research with Becton Dickinson Biosciences in San Jose, California from 2019-2021, where he led a team of MDs and PHDs driving scientific strategy for a cutting-edge immuno-oncology focused portfolio. From 2018-2019, Dr. Arshad served as Head of Medical Affairs, Immunology, Global Markets for Sanofi Genyzyme, and Chief Medical Officer, Head of Clinical Research and Medical Affairs for Humanigen, Inc. from 2016-2018. Prior to that, he held leadership positions with XOMA Corporation, Genentech, Inc., Merck & Co., Inc., and Pfizer Inc. Dr. Arshad holds a M.B.B.S (Bachelor of Medicine, Bachelor of Surgery) from University of Punjab, MD from Educational Commission for Foreign Medical Graduates (ECFMG), and a M.B.A. degree from George Washington University.
塔里克·阿尔沙德,在2021年5月加入Qualigen之前,阿尔沙德博士曾于2019年至2021年在加利福尼亚州圣何塞的Becton Dickinson Biosciences担任全球医疗事务和临床研究主管,在那里,他领导了一个由医学博士和博士组成的团队,推动以免疫肿瘤学为重点的前沿产品组合的科学战略。从2018年至2019年,Arshad博士担任赛诺菲 Genyzyme全球市场医疗事务、免疫学主管,从2016年至2018年担任Humanigen公司首席医疗官、临床研究和医疗事务主管。在此之前,他曾在XOMA公司、基因泰克、默克制药公司和辉瑞公司担任领导职务。阿尔沙德博士拥有旁遮普大学的医学学士学位、外国医学毕业生教育委员会(ECFMG)的医学学士学位和乔治华盛顿大学的工商管理硕士学位。
Tariq Arshad,Prior to joining Qualigen in May 2021, Dr. Arshad was Global Head of Medical Affairs and Clinical Research with Becton Dickinson Biosciences in San Jose, California from 2019-2021, where he led a team of MDs and PHDs driving scientific strategy for a cutting-edge immuno-oncology focused portfolio. From 2018-2019, Dr. Arshad served as Head of Medical Affairs, Immunology, Global Markets for Sanofi Genyzyme, and Chief Medical Officer, Head of Clinical Research and Medical Affairs for Humanigen, Inc. from 2016-2018. Prior to that, he held leadership positions with XOMA Corporation, Genentech, Inc., Merck & Co., Inc., and Pfizer Inc. Dr. Arshad holds a M.B.B.S (Bachelor of Medicine, Bachelor of Surgery) from University of Punjab, MD from Educational Commission for Foreign Medical Graduates (ECFMG), and a M.B.A. degree from George Washington University.